Reduced Segmentation of Lesions Is Comparable to Whole-Body Segmentation for Response Assessment by PSMA PET/CT: Initial Experience with the Keyhole Approach.
PET/CT
PSMA-TV
SUV
prostate cancer
radioligand therapy
taxane
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
26 Apr 2022
26 Apr 2022
Historique:
received:
21
03
2022
revised:
19
04
2022
accepted:
21
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
(1) Background: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-derived parameters, such as the commonly used standardized uptake value (SUV) and PSMA-positive tumor volume (PSMA-TV), have been proposed for response assessment in metastatic prostate cancer (PCa) patients. However, the calculation of whole-body PSMA-TV remains a time-consuming procedure. We hypothesized that it may be possible to quantify changes in PSMA-TV by considering only a limited number of representative lesions. (2) Methods: Sixty-five patients classified into different disease stages were assessed by PSMA PET/CT for staging and restaging after therapy. Whole-body PSMA-TV and whole-body SUV
Identifiants
pubmed: 35625388
pii: biology11050660
doi: 10.3390/biology11050660
pmc: PMC9137844
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : IZKF Würzburg
ID : Z-02/85
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):602-612
pubmed: 29185010
J Nucl Med. 2017 Dec;58(12):1962-1968
pubmed: 28522740
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072
pubmed: 30569186
J Clin Oncol. 2011 Sep 20;29(27):3695-704
pubmed: 21859988
Prostate. 2020 Jan;80(1):74-82
pubmed: 31614001
J Nucl Med. 2019 Sep;60(9):1277-1283
pubmed: 30850484
Ann Nucl Med. 2019 Oct;33(10):766-775
pubmed: 31338731
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):469-476
pubmed: 32617640
J Clin Med. 2020 May 08;9(5):
pubmed: 32397223
J Nucl Med. 2020 Dec;61(12):1786-1792
pubmed: 32332147
Eur J Radiol. 2021 Mar;136:109556
pubmed: 33485127
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881